1-8 of 8
David Patton
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative

Richard F. Little, Megan Othus, Sarit Assouline, Sherry Ansher, Ehab L. Atallah, R. Coleman Lindsley, Boris Freidlin, Steven D. Gore, Lyndsay Harris, Christopher S. Hourigan, S. Percy Ivy, Shahanawaz Jiwani, Erin Langan, Selina M. Luger, Laura C. Michaelis, Olatoyosi Odenike, David Patton, Miguel-Angel Perales, Jerald P. Radich, Bhanu Ramineni, Jesse J. Salk, Patrick Stiff, Wendy Stock, Richard M. Stone, Geoffrey L. Uy, P. Mickey Williams, Brent L. Wood, Katherine H Worthington, Laura M Yee, Amer M. Zeidan, Jianqiao Zhang, Mark R. Litzow, Harry P. Erba
Journal: Blood
Blood (2022) 140 (Supplement 1): 9057–9060.
https://doi.org/10.1182/blood-2022-169307
Published: 2022
Journal Articles

Phase I Results of Combination Gemcitabine and Bortezomib (Velcade®) for Relapsed/Refractory Nodal T-Cell Non-Hodgkin Lymphoma (T-NHL) and Aggressive B-Cell NHL (B-NHL).

Andrew M. Evens, DO, MS, Leo I. Gordon, MD, David Patton, BS, Steven T. Rosen, MD, Jane N. Winter, MD, Justin Kline, MD, Koen Van Besien, MD, Sonali M. Smith, MD
Journal: Blood
Blood (2008) 112 (11): 2005.
https://doi.org/10.1182/blood.V112.11.2005.2005
Published: 2008
Journal Articles

A Phase I/II Trial of Radioimmunotherapy (RIT) with 90 Yttrium-Ibritumomab Tiuxetan (Zevalin®; 90 Y-Zevalin) Combined with the Redox-Active Agent Motexafin Gadolinium (MGd): Prompt and High Remission Rates in Patients with Rituximab-Refractory Non-Hodgkin’s Lymphoma (NHL).

Andrew M. Evens, DO, MS, Stewart Spies, MD, David Patton, MS, Irene Helenowski, MS, Borko Jovanovic, PhD, Sarah Miyata, RN, ACNP, Elizabeth Hamilton, RN, CNP, M. Wayne Saville, MD, Richard A. Miller, MD, Jane N. Winter, MD, Leo I. Gordon, MD
Journal: Blood
Blood (2007) 110 (11): 2558.
https://doi.org/10.1182/blood.V110.11.2558.2558
Published: 2007
Journal Articles

90 Y Ibritumomab Tiuxetan (Zevalin®; 90 YZ) Doses Calculated To Deliver up to 1500 cGy to Critical Organs May Be Safely Combined with High-Dose BEAM and Autotransplant in NHL.

Jane N. Winter, MD, David Inwards, M.D., Stewart Spies, M.D., Gregory Wiseman, M.D., David Patton, B.S., William Erwin, M.S., Alfred Rademaker, Ph.D., Stephanie Williams, M.D., Martin S. Tallman, M.D., Ivana Micallef, M.D., Jayesh Mehta, M.D., Seema Singhal, M.D., Andrew Evens, D.O., Michael Zimmer, Ph.D., Arturo Molina, M.D., Christine White, M.D., Leo I. Gordon, M.D.
Journal: Blood
Blood (2006) 108 (11): 330.
https://doi.org/10.1182/blood.V108.11.330.330
Published: 2006
Journal Articles

Durable Event-Free and Overall Survival (EFS/OS) in Mantle Cell Lymphoma (MCL) without Rituximab: Long-Term Follow-Up of a Phase II Trial with Intensive Chemotherapy (CTAP/VMAC) Followed by Autologous Hematopoietic Stem Cell Transplant (aHSCT).

Andrew M. Evens, DO, MS, Jane N. Winter, MD, Nanjiang Hou, MS, Fred Rademaker, PhD, Katalin Kelemen, MD, Beverly Nelson, MD, David Patton, BS, Olga Frankfurt, MD, Stephanie Williams, MD, Seema Singhal, MD, Martin S. Tallman, MD, Steven T. Rosen, MD, Jayesh Mehta, MD, Leo I. Gordon, MD
Journal: Blood
Blood (2006) 108 (11): 2448.
https://doi.org/10.1182/blood.V108.11.2448.2448
Published: 2006
Journal Articles

Combination of Motexafin Gadolinium (MGd) with 90 Y Ibritumomab Tiuxetan (Zevalin®; 90 Yttrium-Zevalin) Radioimmunotherapy (RIT) Produces High Complete Remission Rates in Relapsed Rituximab-Refractory Follicular Non- Hodgkin’s Lymphoma (NHL).

Andrew M. Evens, DO, MS, David Patton, BS, Stewart Spies, MD, Smitha Sivaraman, PhD, M.Wayne Saville, MD, See Phan, MD, Richard Miller, MD, Leo I. Gordon, MD
Journal: Blood
Blood (2005) 106 (11): 2450.
https://doi.org/10.1182/blood.V106.11.2450.2450
Published: 2005
Journal Articles

Autologous Stem Cell Transplantation (AuSCT) with Total Lymphoid Irradiation (TLI) and High-Dose Chemotherapy (CT) Results in High Survival Rates for “Poor-Prognosis” Relapsed/Refractory (R/R) Hodgkin’s Disease (HD): Multivariate Analysis of Outcome Shows Marked Benefit for TLI in a Prospective Phase I/II Trial.

Andrew M. Evens, DO, MS, Alfred Rademaker, PhD, Bharat B. Mittal, MD, Jessica K. Altman, MD, David Patton, BS, Lynne Kaminer, MD, Seema Singhal, MD, Daina Variakojis, MD, Stephanie Williams, MD, Martin S. Tallman, MD, Jayesh N. Mehta, MD, Jane N. Winter, MD, Leo I. Gordon, MD
Journal: Blood
Blood (2005) 106 (11): 2080.
https://doi.org/10.1182/blood.V106.11.2080.2080
Published: 2005
Journal Articles

90 Y Ibritumomab Tiuxetan (Zevalin®; 90YZ) Doses Higher Than .4 mCi/kg May Be Safely Combined with High-Dose Beam and Autotransplant: The Role for Dosimetry.

Jane N. Winter, M.D., David J. Inwards, M.D., Stewart Spies, M.D., Gregory Wiseman, M.D., David Patton, William Erwin, M.S., Alfred Rademaker, Ph.D., Stephanie F. Williams, M.D., Martin S. Tallman, M.D., Ivana Micallef, M.D., Jayesh Mehta, M.D., Seema Singhal, M.D., Michael Zimmer, Ph.D., Arturo Molina, M.D., Christine White, M.D., Leo I. Gordon, M.D.
Journal: Blood
Blood (2004) 104 (11): 1162.
https://doi.org/10.1182/blood.V104.11.1162.1162
Published: 2004